secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2026-11-09T11:59:49+00:00
Accession:  0001645113-26-000085
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

FDA issues Not Approvable Letter for Novocure's Optune Mya PMA in NSCLC brain metastases
--------------------------------------------------------------------------------

- FDA determined uncertainty around degree of clinical benefit of Optune Mya prevented approval; no safety concerns were raised.
- Optune Mya sought approval for adult patients with brain metastases from non-small cell lung cancer following stereotactic radiation.
- Novocure plans to meet with the FDA to explore options for approval that would not require additional clinical studies.
- Company said there can be no assurance that discussions or future submissions will lead to approval; announced November 9, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511326000085/0001645113-26-000085-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511326000085/nvcr-20261109.htm
  HTML page:      https://secwatch.observer/filing/0001645113-26-000085

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer